# Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)

> **NCT07173933** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **GeneCradle Inc** · enrollment: 15 (estimated)

## Conditions studied

- Wilson Disease

## Interventions

- **GENETIC:** GC310

## Key facts

- **NCT ID:** NCT07173933
- **Lead sponsor:** GeneCradle Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2027-04
- **Final completion:** 2027-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07173933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07173933, "Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07173933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*